Trial Profile
A Phase I/II Trial to Evaluate the Safety and Immunogenicity of a Helper Peptide Vaccine Plus CTLA-4 Blockade in Melanoma Patients (Mel62; 6PAC)
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Montanide ISA-51; Peptide vaccines; Peptide vaccines
- Indications Brain metastases; Malignant melanoma; Skin cancer; Uveal melanoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms Mel62; 6PAC
- 27 Feb 2020 Status changed from active, no longer recruiting to discontinued.
- 07 Jun 2019 Planned End Date changed from 1 Aug 2019 to 1 Oct 2019.
- 07 Jun 2019 Planned primary completion date changed from 1 Aug 2019 to 1 Oct 2019.